Get started
Author

Vanessa Zann

Observed name: V. Zann
ORCID: 0000-0003-0747-181X
Observed ORCID: 0000-0003-0747-181X
OpenAlex ID: A5083976305
On the Colonic Bacterial Metabolism of Azo-Bonded Prodrugsof 5-Aminosalicylic Acid
2014 · Tiago Sousa, Vipul Yadav, et al. · Journal of Pharmaceutical Sciences · 149
Chain length affects pancreatic lipase activity and the extent and pH–time profile of triglyceride lipolysis
2015 · Paloma Benito-Gallo, Alessandro Franceschetto, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 92
PDF
Assessment of Safety, Tolerability, Pharmacokinetics, and Pharmacological Effect of Orally Administered CORT125134: An Adaptive, Double‐Blind, Randomized, Placebo‐Controlled Phase 1 Clinical Study
2017 · Hazel Hunt, Kirsteen Donaldson, et al. · Clinical Pharmacology in Drug Development · 68
PDF
Safety, Pharmacokinetics, and Pharmacodynamics of ME-401, an Oral, Potent, and Selective Inhibitor of Phosphatidylinositol 3-Kinase P110δ, Following Single Ascending Dose Administration to Healthy Volunteers
2018 · Ofir Moreno, Todd Butler, et al. · Clinical Therapeutics · 28
PDF
Novel formulation of abiraterone acetate might allow significant dose reduction and eliminates substantial positive food effect
2017 · Tamás Solymosi, Zsolt Ötvös, et al. · Cancer Chemotherapy and Pharmacology · 26
Linking in Vitro Lipolysis and Microsomal Metabolism for the Quantitative Prediction of Oral Bioavailability of BCS II Drugs Administered in Lipidic Formulations
2016 · Paloma Benito-Gallo, Maria Marlow, et al. · Molecular Pharmaceutics · 17
Palatability and physical properties of potassium-binding resin RDX7675: comparison with sodium polystyrene sulfonate
2017 · Vanessa Zann, John McDermott, et al. · Drug Design Development and Therapy · 15
PDF
Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology
2022 · Debra Tompson, Mark Whitaker, et al. · Pharmaceutical Research · 13
PDF
Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772
2021 · Debra J. Tompson, Mark Whitaker, et al. · Pharmaceutical Research · 13
PDF
Digoxin net secretory transport in bronchial epithelial cell layers is not exclusively mediated by P-glycoprotein/MDR1
2013 · Victoria Hutter, David Y.S. Chau, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 13
PDF
Evaluation of layers of the rat airway epithelial cell line RL-65 for permeability screening of inhaled drug candidates
2012 · V. Hutter, C. Hilgendorf, et al. · European Journal of Pharmaceutical Sciences · 4
PDF
Discovery and Model‐Informed Drug Development of a Controlled‐Release Formulation of Nonracemic Amisulpride that Reduces Plasma Exposure but Achieves Pharmacodynamic Bioequivalence in the Brain
2024 · Seth C. Hopkins, Siriporn Toongsuwan, et al. · Clinical Pharmacology & Therapeutics · 3
An Evaluation of the Pharmacodynamics, Safety, and Tolerability of the Potassium Binder RDX7675
2018 · Bertram Pitt, Vanessa Zann, et al. · The Journal of Clinical Pharmacology · 2
PDF
Smart Lipid-Based Drug Delivery Systems
2016 · Paloma Benito-Gallo, Pavel Gershkovich, et al. · IMPERIAL COLLEGE PRESS eBooks · 2
Formulation development and a Phase 1 clinical study of PF614-MPAR, an oxycodone prodrug with oral opioid overdose protection
2026 · D. Lynn Kirkpatrick, Linda A. Pestano, et al. · Journal of Opioid Management · 1
PDF
Co-administering clofazimine with infant formula enhances its oral bioavailability in rats and pigs
2025 · Thomas Eason, Ellie Ponsonby-Thomas, et al. · European Journal of Pharmaceutics and Biopharmaceutics · 1
A randomized, placebo‐controlled first‐in‐human study of oral TQS‐168 in healthy volunteers: Assessment of safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect
2024 · Jonas Hannestad, Steven Smith, et al. · Clinical and Translational Science · 1
PDF
Oral Site‐Directed Drug Delivery and Influence on PK
2021 · Peter Scholes, Vanessa Zann, et al. · Wiley eBooks · 1
Abstract CT157: Clinical pharmacokinetics and pharmacodynamics of ME-401, an oral, potent and selective inhibitor of phosphatidylinositol 3-kinase P110δ, following single ascending dose administration to healthy volunteers
2016 · Ofir Moreno, Robert Imani, et al. · Cancer Research · 1
Unexpected Effect of Digestion Products of Infant Formula in Enhancing the Solubilisation of Tolfenamic Acid During Digestion
2026 · Thomas Eason, Malinda Salim, et al. · Pharmaceutics
PDF
Appendix: Formulation development and a Phase 1 clinical study of PF614-MPAR, an oxycodone prodrug with oral opioid overdose protection
2026 · D. Lynn Kirkpatrick, Linda A. Pestano, et al. · Journal of Opioid Management
PDF
Permeability
2021 · Chris Roe, Vanessa Zann · Wiley eBooks
Novel formulation of abiraterone acetate with significantly higher bioavailability and eliminated food effect might allow higher abiraterone exposure and better patient outcome.
2018 · Hristos Glavinas, Tamás Solymosi, et al. · Journal of Clinical Oncology
Abstract 14911: RDX227675, the Calcium Salt of a Novel Polystyrene Sulfonate-Based Resin, Reduces Potassium Absorption in Healthy Volunteers
2016 · Vanessa Zann, Chris Roe, et al. · Circulation
14C Microtracer Approaches to Inform Formulation Development Strategies in Early Clinical Drug Development
2016 · Vanessa Zann
Works count: 29
Citation count: 450
H-index: 10
I10-index: 10
Year
Topic
Type